The age–male–albumin–bilirubin–platelets (aMAP) risk scoring system was recently created to assess HCC risk in chronic hepatitis patients, including HCV carriers with SVR, again both in the presence or absence of cirrhosis. The gene discussed is ALB; the disease is Cirrhosis.